Skip to main content

Advertisement

Table 4 Summary of subgroup and sensitivity analysis of eligible studies included in a meta-analysis of prolonged infusion versus intermittent infusion of β-lactams in hospitalized patients†

From: Does prolonged β-lactam infusions improve clinical outcomes compared to intermittent infusions? A meta-analysis and systematic review of randomized, controlled trials

Sub-group analysis Studies
Included
Mortality
Risk Ratio (95%
CI)
I2 % Studies
Included
Clinical Cure
Risk Ratio (95%
CI)
I2%
β-lactam subclasses       
Penicillins 2 0.62 (0.19-2.03) 0 3 0.77 (0.46-1.30) 0
Cephalosporins 4 0.95 (0.35-2.63) 50 8 1.04 (0.92-1.18) 35
Carbapenems 2 1.08 (0.64-1.82) 0 2 1.00 (0.69-1.44) 0
Continuous infusion 6 0.80 (0.42-1.50) 22 10 1.01 (0.92-1.10) 16
Not funded by pharmaceutical industry 5 0.80 (0.37-1.73) 26 5 1.15 (0.85-1.57) 57
Equivalent daily dose of β-lactam antibiotic 5 1.30 (0.59-2.87) 0 6 1.06 (0.90-1.25) 48
Sensitivity-analysis       
Intention-to-treat analysis 8 1.10 (0.75-1.60) 0 8 1.05 (0.93-1.19) 21
  1. † Reference group is intermittent β-lactam infusion